Rectal Douching Practices Associated with Anal Intercourse: Implications for the Development of a Behaviorally Congruent HIV-Prevention Rectal Microbicide Douche.
Administration, Rectal
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Infective Agents
/ administration & dosage
Female
HIV Infections
/ prevention & control
Health Surveys
Humans
Internet
Male
Middle Aged
Patient Acceptance of Health Care
Rectum
/ drug effects
Sexual and Gender Minorities
Tenofovir
/ administration & dosage
Therapeutic Irrigation
/ methods
United States
Young Adult
Enemas
HIV-prevention
Rectal douching
Rectal microbicides
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
pubmed:
12
11
2018
medline:
31
8
2019
entrez:
12
11
2018
Statut:
ppublish
Résumé
Tenofovir administration via rectal douching results in higher rectal-mucosa drug concentration than oral administration. Many who engage in receptive anal intercourse (RAI) use cleansing rectal douches. To inform development of a behaviorally-congruent tenofovir douche, 4751 individuals ≥ 18 years-old, born male, from all US states/territories, who engaged in anal intercourse responded to an online survey. Of those who reported RAI in the prior 3 months, 80% douched beforehand, 82% within 1 h, mean 2.9 consecutive applications; 27% douched afterwards, 83% within 1 h, mean 1.7 consecutive applications. Among multidose users, 78% applied doses within 2 min, and 76% retained liquid < 1 min. Most used tap water (89%) in an enema bottle (50%) or rubber bulb (43%), and douched for cleanliness (97%), to avoid smelling bad (65%), and to enhance pleasure (24%). 98% reported high likelihood of using an HIV-prevention douche. An ideal product will protect within a user's typical number of applications, within 1 h, and be dissolvable in tap water.
Identifiants
pubmed: 30415431
doi: 10.1007/s10461-018-2336-6
pii: 10.1007/s10461-018-2336-6
pmc: PMC6510640
mid: NIHMS1512210
doi:
Substances chimiques
Anti-Infective Agents
0
Tenofovir
99YXE507IL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1484-1493Subventions
Organisme : NIMH NIH HHS
ID : P30 MH043520
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI113127
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
ID : U19-AI113127
Organisme : National Institute of Mental Health
ID : P30-MH43520
Références
Sex Transm Dis. 1999 Nov;26(10):572-8
pubmed: 10560721
Vaccine. 2006 Mar 15;24(12):2094-101
pubmed: 16332402
AIDS Behav. 2008 Nov;12(6):860-6
pubmed: 17705033
Sex Transm Dis. 2010 Apr;37(4):228-33
pubmed: 19959973
AIDS. 2010 Jul 17;24(11):1749-56
pubmed: 20597165
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
Curr Opin HIV AIDS. 2012 Nov;7(6):534-41
pubmed: 23032737
AIDS Patient Care STDS. 2013 Feb;27(2):77-84
pubmed: 23373663
J Int Assoc Provid AIDS Care. 2013 Jul-Aug;12(4):278-83
pubmed: 23422742
AIDS Patient Care STDS. 2013 Apr;27(4):248-54
pubmed: 23565928
AIDS Res Hum Retroviruses. 2013 Nov;29(11):1487-95
pubmed: 23885722
Sex Transm Infect. 2014 Feb;90(1):33-5
pubmed: 23966338
Curr Opin HIV AIDS. 2013 Nov;8(6):565-71
pubmed: 24100877
BMC Infect Dis. 2014 Feb 21;14:95
pubmed: 24555695
AIDS Behav. 2014 Sep;18(9):1734-45
pubmed: 24858481
J Control Release. 2015 Jul 10;209:280-7
pubmed: 25937321
AIDS Behav. 2016 Nov;20(11):2578-2587
pubmed: 26597502
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
AIDS Educ Prev. 2016 Feb;28(1):1-10
pubmed: 26829253
N Engl J Med. 2016 Dec;375(22):2121-2132
pubmed: 26900902
Pharm Res. 2016 Jul;33(7):1649-56
pubmed: 26975357
Sex Transm Infect. 2017 Sep;93(6):431-437
pubmed: 28108702
AIDS Behav. 2018 Feb;22(2):412-420
pubmed: 28688029
AIDS Behav. 2018 Feb;22(2):388-401
pubmed: 28825142
AIDS Behav. 2018 Apr;22(4):1288-1294
pubmed: 29098455
AIDS Behav. 2017 Dec;21(12):3336-3345
pubmed: 29119473